A number of monoclonal antibodies (mAbs) have been studied for their ability to enhance immune responses. Although these antibodies are effective in pre-clinical and clinical studies, they are costly and have occasionally been associated with adverse effects such as autoimmunity and cytokine storm. Numerous studies have shown that treatment of mice with an agonistic mAb, clone DTA-1, targeting murine glucocorticoid-induced tumor necrosis factor receptor (GITR) results in enhanced immune responses in tumor-bearing animals. Herein, we evaluate the novel approach of transfecting dendritic cell (DC) with mRNA encoding the heavy and light chain of the anti-GITR mAb. We show the induction of significantly enhanced tumor immunity by vaccinating with a combination of anti-GITR-secreting DC and tumor antigen-presenting DC. This enhancement is comparable to that seen with systemically delivered mAb along with the antigen-presenting DC. Importantly, when anti-GITR was delivered using RNAtransfected DC, we observed no evidence of autoimmune hypopigmentation in any tumor-free mice. We also show enhanced induction of cytotoxic T-lymphocyte responses, which is only observed when the antigen-presenting and antibody-secreting DC are co-injected at the same site. To illustrate the broad utility of this strategy, we show that DC transfected with mRNA encoding GITRligand/Fc fusion protein is also an effective tumor vaccine adjuvant.
Introduction
The ultimate goal of active tumor immunotherapy is to induce a robust, long-lasting, tumor-specific immune response that is capable of eliminating, at the least, the minimal disease remaining after removal of the primary tumor. 1 A strategy that has shown considerable promise in this regard is that of loading dendritic cells (DC) generated ex vivo with antigen for use as a vaccine. Numerous studies have shown that DC loaded with antigen in the form of peptide, protein, DNA, RNA or virus can stimulate anti-tumor responses directed against not only mutated proteins but also normal cellular products that are over-expressed in cancer cells. [2] [3] [4] However, although this and other strategies have been able to show a vaccine-induced increase in tumor-specific T cells, they frequently fall short of clearing pre-existing disease. 1 It is becoming clear that one reason for this insufficiency is that the immune system has developed an effective, active method of regulating itself and its reaction to self-antigens, including those expressed in tumors. 5 This suppression is mediated by CD4 þ CD25 þ regulatory T cells (Tregs) that accumulate both intratumorally in which they may suppress tumoricidal cytotoxic T lymphocytes (CTLs), [5] [6] [7] [8] [9] [10] [11] [12] as well as at the site of DC/Tcell interactions in the draining lymph nodes (LNs), inhibiting the induction of antigen-specific T cells.
Monoclonal antibodies (mAbs) that bind receptors involved in the modulation of the immune response have been tested for their ability to act as adjuvants in immunotherapy protocols. Studies in mice have shown that these systemically delivered mAbs can produce the desired effect of enhancing protection against tumors and infectious diseases and many mAbs are currently in clinical trials with promising preliminary results. 13, 14 However, immunomodulatory mAbs have been associated with adverse side-effects associated with their systemic administration, as observed in clinical trials with anti-CTLA-4 [15] [16] [17] [18] [19] and systemic and non-specific induction of inflammatory mediators as seen in the trial of the superagonistic mAb targeting CD28. 20 Another consideration in using these mAbs is that they are generally given in high doses (1-20 mg kg
À1
) over a period of time, resulting in expensive treatment costs. 13, 14, 21 An antibody that has been extensively tested in mice targets the glucocorticoid-induced tumor necrosis factor receptor (GITR). [22] [23] [24] [25] [26] [27] [28] GITR, a member of the tumor necrosis factor receptor superfamily, is constitutively expressed on Tregs but it is also expressed at low levels on multiple immune cells, including T cells, natural killer cells and B cells in which it is upregulated on activation. 7, 23, [29] [30] [31] Treatment of mice with an agonistic anti-GITR mAb (anti-GITR), clone DTA-1, alone has been shown to cause exacerbated autoimmune disease in susceptible mice and enhanced anti-viral and anti-tumor immune responses in disease-bearing animals. 22, [24] [25] [26] [27] [28] When combined with DNA immunization against xenogeneic melanoma-related antigens, DTA-1-treated mice showed increased T-cell responses and protection from tumor challenge. 22 Interestingly, these mice also showed an increase in autoimmune hypopigmentation. 22 Together, these data indicate that treatment with agonistic anti-GITR, alone or as an adjunct to active immunization, increases the ability to break immune tolerance. Although there is some debate, recent studies indicate that this enhanced immune response is due to ligation of GITR on the effector cells, making them resistant to suppression, rather than on the Tregs themselves. 23, 27, [29] [30] [31] [32] [33] In the current study, we examine the effects of combining DC-based anti-tumor vaccination with stimulation of GITR. To achieve GITR stimulation, we evaluate the novel approach of transfecting DC with the mRNA encoding the heavy (H) and light (L) chain of the mAb or mRNA encoding a GITR-ligand (L)/Fc fusion protein chimera. We show that the transfected cells make functional protein that binds murine GITR. We evaluate the utility of this approach in the stringent murine B16 melanoma immunotherapy model and show that mice treated with a combination of anti-GITR-secreting DC and DC-tumor vaccine have a significantly longer time to tumor progression, with 50-60% remaining tumor-free. The antigen-presenting and antibody-secreting DC must be injected at the same site for enhancement of T-cell responses, suggesting that anti-GITR-mediated stimulation of local immune responses has a significant systemic anti-tumor effect. The anti-tumor response generated by vaccinating with a combination of anti-GITR-secreting DC and tumor antigen-presenting DC is comparable to that seen with systemically delivered anti-GITR mAb along with the DC-tumor vaccine. Importantly, no evidence of autoimmune hypopigmentation (vitiligo) was observed in any tumor-free mice vaccinated with antigen presenting DC and anti-GITR-secreting DC. We also show that DC transfected with RNA encoding a GITR-L/Fc fusion protein enhances tumor vaccinemediated anti-tumor immunity, similar to that observed with anti-GITR-secreting DC.
Materials and methods
Mice C57BL/6 mice (H-2 b ) (4-to 6-week-old) were obtained from the Jackson Laboratory, Bar Harbor, ME. In conducting the research described in this paper, the investigators adhered to the 'Guide for the Care and Use of Laboratory Animals' as proposed by the committee on care of Laboratory Animal Resources Commission on Life Sciences, the National Research Council. The facilities at the Duke Vivarium are fully accredited by the American Association for Accreditation of Laboratory Animal Care, and all the studies were approved by the Duke University IACUC.
Cell lines and reagents
The F10.9 clone of B16 melanoma (B16/F10.9) of C57BL/6 origin is a highly metastatic, poorly immunogenic and a low class I-expressing cell line. Other cell lines used were DTA-1 cells (anti-murine GITR mAb-secreting hybridoma cells, kindly provided by Dr Shimon Sakaguchi), Chinese hamster ovary (CHO) cells, EL4 thymoma cells and B16/F10.9-OVA cells. Cells were maintained in Dulbecco's Modified Eagle Medium supplemented with 10% fetal calf serum, 25 mM Hepes, 2 mM L-glutamine and 1 mM sodium pyruvate. DTA-1 anti-GITR mAb and the corresponding rat IgG2b isotype control were obtained from Bio X Cell Culture Services (West Lebanon, NH).
RNA
Cloning of chicken ovalbumin (OVA) and murine tyrosinase-related protein (TRP-2), telomerase (TERT) and actin mRNA. Creation of pSP73-Sph/A64 and cloning of pSP73-Sph/TRP-2/A64, pSP73-Sph/TERT/ A64, pGEM4Z/OVA/A64 and pGEM4Z/murine actin/ A64 was previously described. [34] [35] [36] Cloning of rat IgG and DTA-1 heavy and light chains. The hybridoma DTA-1 was grown in Dulbecco's Modified Eagle Medium/10% fetal calf serum with 10 ng ml À1 murine IL-4. Total RNA was isolated with the RNeasy mini kit (Qiagen, Valencia, CA). Total RNA from rat spleen was obtained from Biochain Institute, Inc. 0 . The resulting PCR fragments were digested with HindIII and EcoRI and cloned into the HindII and EcoRI sites of the plasmid pSP73-Sph/A64, which has a T7 promoter and 64T nucleotides that allow for the production of in vitro transcribed RNA with a polyA tail of 64 residues.
Cloning of murine GITR-L/murine Fc fusion protein. Total RNA was isolated from lipopolysaccharide-treated murine DC. A total of 5 mg was used in a reverse transcription reaction as described above. Murine GITR-L was amplified by PCR using the primers 5 0 -ATATATG GCCTAGCGGCCACTGCCATCGAGTCCTGCAT-3 0 and 5 0 -ATATATGTCGACGGCCTAACAGGCCCTAA GAGATGAATGGTAGATC-3 0 . Murine IgG1 Fc CH2 and CH3 regions were amplified from IMAGE clone 5039226 (ATCC, Manassas, VA) with the primers 5 0 -ATATATACCGGTGGTTGTAAGCCTTGCATATG-3 0 and 5 0 -ATATATGGCCGCTAGGGCCAGTTTACCAG GAGAGTGGGAGAG-3 0 . The resulting fragments were cut with SfiI alone or SfiI and PinAI and ligated into pSP73-Sph/A64 containing the gp96 signal sequence followed by a PinAI site.
In vitro transcription. All plasmids were digested with SpeI for use as a template in in vitro transcription reactions except for DTA-1 L chain, which contains an SpeI site and was digested with NotI. In vitro transcription was carried out with the mMessage mMachine T7 (Ambion, Austin, TX) according to the manufacturer's protocol. RNA was purified with the RNeasy Mini Kit.
Generation and electroporation of DC DC were generated from bone marrow precursors as described previously 34, 35 in RPMI-5% fetal calf serum with granulocyte macrophage-colony stimulating factor (GM-CSF) (15 ng ml
À1
) and IL-4 (10 ng ml
). GITR expression on bone marrow-derived DC was low-tonegative (mature DCp15-18% and immature DCp10-12%, data not shown).
After 7 days the non-adherent cells were harvested as DC and resuspended in Opti-MEM (Invitrogen Grand Island, NY) at 2.5-3 Â 10 7 cells per ml. Cells were electroporated in 2-mm cuvettes (200 ml) at 300 V for 500 ms using an Electro Square Porator (ECM 830, BTX, San Diego, CA). Tumor antigen RNA was used at 3 mg 5 RNA-transfected DC/ear pinna in 50 ml PBS for a total of 100 ml per mouse. For experiments testing the combination of tumor antigen RNA-transfected DC and mAb-encoding RNA-transfected DC, mice were immunized with 1-1.5 Â 10 5 DC for each group for a combined 2-3 Â 10 5 DC/ear pinna in 50 ml PBS for a total of 100 ml per mouse. Anti-GITR mAb was injected intraperitoneally. Tumor growth was evaluated every other day starting on day 10. Mice were killed once the tumor size reached 20 mm. Tumor-free mice were killed after 65-70 days.
Experimental metastasis model: C57BL/6 (H-2 b ) mice were injected with 3 Â 10 4 B16/F10.9 tumor cells intravenously in the tail vein. Mice were vaccinated 2 days after tumor injection as indicated above. Mice were killed on the basis of the metastatic death in the control groups (28-30 days after tumor injection). Metastatic loads were assayed by weighing the lungs.
CTL induction in vivo
Cells were harvested from LNs or spleens 7-10 days after immunization and depleted of RBC followed by adherence for 1 h. In total, 10 7 non-adherent lymphocytes were cultured with 2 Â 10 5 stimulator cells (DC electroporated with antigen-encoding RNA) in 5 ml of RPMI with 10% fetal calf serum, 1 mM sodium pyruvate, 100 IU ml À1 penicillin, 100 mg ml À1 streptomycin and 5 Â 10 À5 M b-mercaptoethanol (supplemented RPMI) per well in a six-well tissue culture plate. Effector T cells were harvested after 5 days followed by a standard europium-release in vitro cytotoxicity assay. 34, 35 In vitro Treg suppression assays Proliferation assay: Auricular LNs were harvested 5 days after immunization. A total of 10 6 cells ml À1 in PBS were labeled with 0.5 mM carboxyfluorescein succinimidyl ester (CFSE) at room temperature for 5 min. Cells were washed twice before use. 
Statistical analysis
For tumor studies, comparison between two groups was done using the log-rank test (Mantel-Haenszel test). Additional comparisons between groups were done by determining the median time to tumor onset for each group. For the experimental metastasis tumor model, the different experimental groups within the study were compared using the Kruskal-Wallis test. The MannWhitney U-test was used to compare differences in lung weights between two groups. Statistical significance in immune assays comparing two groups was done using paired two-tailed Student's t-test. A probability of o0.05 (Po0.05) was considered statistically significant.
Results
Cells transfected with antibody-encoding RNA produce antibodies that bind their specific target To show that we could generate mAbs by transfecting cells with mAb-encoding RNA, we electroporated CHO cells with either total RNA from anti-mouse GITR hybridoma cells, DTA-1 (DTA-1 total RNA) 27 or with IVT RNA encoding the heavy (H) and light (L) mAb chains cloned from DTA-1 (anti-GITR H þ L RNA). The supernatant was harvested 18-20 h after transfection and analyzed for mAb production against cell lines expressing the target protein ( Figure 1 ).
Chinese hamster ovary cells transfected with DTA-1 total RNA or anti-GITR H þ L RNA produce anti-GITR that is as effective as the commercial antibody at binding GITR (Figures 1a and b) . To show the broad utility of this approach with different mAbs, we also show that CHO cells transfected with anti-CD25 H þ L RNA (cloned from anti-CD25-producing hybridoma, PC61) produce anti-CD25 that is as effective as the commercial mAb at binding CD25 (Figures 1a and b) .
As our ultimate goal was to immunize mice with DC transfected with mAb-encoding RNA, we transfected DC with anti-GITR H þ L RNA and showed that supernatant harvested from transfected DC contains anti-GITR mAb (Figure 1c) .
The amounts of anti-GITR mAb produced by RNAtransfected cells were analyzed using enzyme-linked immunosorbent assay. 24-h culture supernatants from CHO cells transfected with anti-GITR H þ L RNA contained 14 ± 0.9 ng of anti-GITR mAb per 10 6 cells, whereas those from DC contained 8.8±0.5 ng of anti-GITR mAb per 10 6 cells (data not shown). Consistent with our previously published studies, protein production in anti-GITR H þ L RNA transfected DC was transient and peaked between 24-48 h after transfection and was not detected after 72 h. 37 (data not shown).
Enhancement of tumor-specific immune responses and induction of long-term anti-tumor immunity with anti-GITR-secreting DC
The crucial demonstration of the validity of our approach was to show that we could enhance anti-tumor responses by immunizing with anti-GITR RNA-transfected DC (anti-GITR-secreting DC) and tumor antigen RNAtransfected DC (antigen-presenting DC) concomitantly. A proof-of-concept experiment was performed with OVA as the tumor antigen in the B16/F10.9-OVA tumor immunotherapy model. Figure 2a shows that OVAspecific DC vaccination synergizes with anti-GITRsecreting DC, resulting in significant enhancement of OVA-specific immunity. Interestingly, mice that were immunized with anti-GITR-secreting DC along with DCactin RNA showed delayed tumor growth in the absence of an antigen-specific immunization. We next evaluated the strategy by vaccinating mice with DC expressing a melanoma-associated antigen, TRP-2, in conjunction with anti-GITR-secreting DC in the murine B16/F10.9 melanoma immunotherapy model. [34] [35] [36] B16/F10.9 represents a non-immunogenic, very aggressive clone of B16 melanoma that is particularly difficult to eradicate. 38 As shown in Figure 2b , a single immunization with TRP-2 RNA-transfected DC resulted in a significant delay in tumor growth but eventually 90% of mice succumbed to tumor. Again, as in Figure 2a , immunization with anti-GITR H þ L RNA-transfected DC in the absence of tumor antigen immunization resulted in a delay in tumor growth. However, when tumor-bearing mice were co-immunized with TRP-2 RNA-transfected DC and anti-GITR H þ L RNA-transfected DC, a significant enhancement of inhibition of tumor growth was observed, with 50% of mice remaining tumor-free (Po0.03). These observations support the view that ligation of GITR enhances both a naturally occurring, although weak, anti-tumor response and synergizes with tumor antigen-specific immune responses induced by vaccination. The magnitude of the anti-tumor response after a single vaccination regimen underscores the importance of GITR signaling in cancer immunotherapy and is remarkable considering the stringent conditions of this immunotherapy protocol.
As the goal of a successful cancer vaccine is to engender long-term tumor-specific immune responses, we investigated whether our approach resulted in sustained longterm memory responses. Mice were implanted with B16/ F10.9 tumor cells followed by one immunization with TRP-2 RNA-transfected DC with control IgG RNA-or anti-GITR H þ L RNA-transfected DC. Tumor-free mice were implanted a second time with the same tumor cells on day 40 to monitor induction of long-term memory responses. When anti-GITR-secreting DC vaccine was combined with a TRP-2-presenting DC vaccine, the result was sustained anti-tumor immunity as indicated by tumor-free survival of 60% of the immunized mice (Figure 2c ).
Delivery of antibodies using DC transfected with antibody-encoding RNA is comparable to systemically delivered antibodies Next, we compared enhancement of tumor immunity by using anti-GITR-secreting DC versus anti-GITR mAb delivered systemically, as has been reported previously. 22, 24, [26] [27] [28] [29] [30] These reports, which show enhancement of tumor responses using anti-GITR mAb delivered (Figure 3a) . One of the major concerns of anti-tumor immunotherapy is an undesirable autoimmune manifestation associated with vaccination, especially in the context of antibody-based vaccines. Such autoimmune manifestations have been shown in other studies using systemic anti-GITR mAb. 22, 24, [26] [27] [28] [29] Consistent with these studies, 
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we saw signs of mild autoimmune hypopigmentation (vitiligo) in 21% of tumor-free mice (3 out of 14) that received systemic anti-GITR mAb in conjunction with TRP-2-presenting DC (Figure 3b) . However, no signs of vitiligo were observed in the tumor-free mice that were given TRP-2-presenting DC and anti-GITR-secreting DC (0 out of 55 mice, P ¼ 0.007).
Enhanced stimulation of T cells requires that the antigen-presenting DC and anti-GITR-secreting DC are co-injected at the same site Figure 2 shows that anti-GITR secreting DC synergizes with antigen-presenting DC to augment anti-tumor immune responses. Recent studies have shown that engagement of GITR on immune cells results in costimulation and enhanced proliferation of T-cell subsets. 23, 26, 32, 33 Therefore, we wanted to evaluate the effect of GITR stimulation in mice vaccinated with anti-GITR-secreting DC on T-cell expansion in the local/draining LN, control/non-draining LN and spleen. Figure 4a depicts significant expansion of CD4 þ and CD8 þ T cells with concurrent expansion of Tregs in the draining LN of mice co-injected with antigenpresenting DC and anti-GITR-secreting DC as compared with antigen-presenting DC and control IgG-secreting DC (Po0.05). Notably, the expansion of T cells was only seen in the draining LN and not the control non-draining LN or spleen for both the groups (Figure 4a and data not shown). 
Next, we analyzed whether antigen-presenting DC and anti-GITR-secreting DC synergistically enhanced effector T-cell function. We therefore examined the effect of immunizing mice with OVA-presenting DC and anti-GITR-secreting DC in the same site (same ear pinna) versus two separate sites (opposite ear pinna). Data in Figure 4b show that the synergistic effects of antigenpresenting DC and anti-GITR-secreting DC on T-cell function were observed only when they are co-injected in the same site. Thus, when mice were injected with OVApresenting and anti-GITR-secreting DC in two separate sites the level of CTL induction was comparable to that obtained with OVA-presenting DC and control IgGsecreting DC (filled triangles and open circles). However, when OVA-presenting and anti-GITR-secreting DC were co-injected at the same site, the level of OVA-specific CTL generated was significantly higher (filled circles, Po0.05), suggesting that the anti-GITR secreted by DC acted in concert with the OVA-presenting DC to stimulate de novo activated OVA-specific T cells. As expected, systemically delivered anti-GITR mAb enhanced OVA-specific CTL, although with a concomitant modest increase in nonspecific lysis, as determined by the lysis of EL4-actin cells (filled squares).
Data in Figures 4a and b indicate that co-immunization with antigen-presenting DC and anti-GITR-secreting DC simultaneously stimulated effector and Tregs. This raised the question of whether these antigen-specific effector T cells had overcome the regulatory effects of the Tregs. Indeed, recent studies have reported that effector T cells co-stimulated with DTA-1 mAb are resistant to Treg suppression. [28] [29] [30] 32, 39 To test this hypothesis, T cells harvested from the draining LN of mice co-injected with anti-GITR-or control IgG-secreting DC and OVApresenting DC were functionally analyzed in the presence of Tregs or control T cells (Tcontrol). As indicated in Supplementary Figure 1 , OVA-specific T cells stimulated with anti-GITR in vivo were resistant to Treg-mediated suppression in an in vitro proliferation assay and cytotoxicity assay. OVA-specific CTLs that were not concurrently stimulated by GITR were less effective in the presence of Treg cells in vitro.
DC transfected with RNA encoding murine GITR-ligand (L)/murine Fc fusion protein enhances tumor-specific immunity The process of generating immunostimulatory mAb to be used in clinical trials involves immunizing mice, generating and screening hybridomas for the presence and function of specific mAb, followed by the generation of Figure 4 Enhanced stimulation of T cells requires co-injection of antigen-presenting dendritic cells (DC) and anti-glucocorticoid-induced TNF receptor (GITR)-secreting DC at the same site. (a) Mice were co-injected with TRP-2 RNA-transfected DC (DC/TRP-2) and anti-GITR H þ L RNA-transfected DC (DC/anti-GITR) in the ear pinna, and 4 days later cells from the draining (auricular) and control (inguinal) lymph node (LN) as well as spleens were harvested. The cells were enumerated, stained for CD4, CD8, CD25 and foxp3, and analyzed by flow cytometry. GITR-mediated expansion of T cells in draining versus control LN is represented as the absolute number of CD4 þ and CD8 þ T cells and
. On the basis of the total number of cells that were isolated from the LN and percent positive cells, the absolute number of cells was determined. Antibody-encoding RNA-transfected dendritic cells D Boczkowski et al humanized mAb that can be safely administered to patients. 13, 21 Availability of these humanized antibodies may be a potential limitation for the clinical translation of our proposed strategy. An alternative is to generate chimeric proteins consisting of the natural ligand of the receptor that is being targeted fused to a protein that will stabilize and, if required, dimerize the ligand. The frequently chosen fusion partner is the Fc portion of immunoglobulin. We constructed a plasmid to generate RNA encoding a murine GITR-L/murine Fc fusion protein (GITR-L fusion protein). As shown in Figure 5a , CHO cells transfected with this RNA produce functional GITR-L fusion protein that is comparable to commercially available anti-GITR mAb at binding GITR-expressing cells. Moreover, the GITR-L fusion protein in the supernatant did not bind CHO cells not expressing GITR (data not shown).
We evaluated the in vivo function of GITR-L fusion protein RNA-transfected DC in the B16/F10.9 tumor immunotherapy model. In Figure 5b , we show a comparable anti-tumor effect using TRP-2 RNA-transfected DC in conjunction with anti-GITR-secreting DC or GITR-L fusion protein-secreting DC.
Next, DC transfected with GITR-L fusion protein encoding RNA were compared with DC transfected with anti-GITR RNA in B16/F10.9 melanoma experimental metastasis model. Mice were intravenously injected with tumor cells followed by immunization with tumor antigen RNA-transfected DC in conjunction with DC transfected with either control IgG RNA, anti-GITR RNA or GITR-L fusion protein RNA. We chose the polypeptide component of TERT as the tumor antigen because we wanted to show the concept of enhancement of tumor-specific immune responses using another tumor antigen in the B16/F10.9 tumor model. 36 As shown in Figure 5c , immunization with TERT RNA-transfected DC in conjunction with control IgG-secreting DC generated anti-tumor immune responses, indicated by the reduction in lung metastasis. Moreover, DC transfected with GITR-L fusion protein RNA is similar in efficacy to DC transfected with anti-GITR RNA in enhancing tumor immunity mediated by the DC-TERT RNA tumor vaccine.
Discussion
This study shows a novel strategy of delivering mAb by transfecting cells with the RNA that encodes the mAb. We transfect DC with RNA encoding the agonistic antimurine GITR, DTA-1, then use those DC in conjunction with tumor-antigen expressing DC to stimulate anti- (Figure 2 ). In addition, a combination of anti-GITRsecreting DC and antigen-presenting DC was as effective in murine tumor immunotherapy experiments as in antigen-presenting DC in conjunction with systemically administered mAb (Figure 3a) . Although a few previous studies have used vaccines consisting of tumor cells transfected with single chain Fv molecules, 40 or GM-CSF-secreting tumor cells stably transfected with secreted single chain Fv anti-CTLA-4, 41 most reports have examined the effects of the systemic administration of antibody. A number of these mAb have been shown to enhance immune responses when delivered systemically. 13, 14 However, human studies have shown that such systemic delivery can lead to adverse effects [15] [16] [17] [18] [19] [20] Thus, an advantage of our strategy is that by co-injecting antibody-secreting and antigen-presenting DC, secretion of antibody in the vicinity of DC presenting tumor antigen to T cells may skew the resulting enhanced immune response toward tumor-specific T cells while decreasing potential non-specific autoimmune reactions. We saw the enhancement of CTL responses only when the anti-GITR-secreting DC and antigen-presenting DC were co-injected at the same site and not when they were injected in opposite sites (Figure 4b) . A possible reason that GITR stimulation of T cells is restricted to the site of injection is that the anti-GITR mAb produced transiently and in limited quantities by 2-3 Â 10 5 anti-GITR-secreting DC injected per mouse does not disseminate systemically. Importantly, we saw no signs of autoimmune vitiligo in the mice vaccinated with anti-GITRsecreting DC (Figure 3b) , whereas 3 out of 14 tumor-free mice injected with anti-GITR mAb systemically, showed signs of autoimmune vitiligo. Furthermore, the use of antibodies as systemic therapeutics is expensive, primarily because of the large doses of antibody used in humans and the cost of manufacture. The proposed approach of delivering antibodies using RNA-transfected cells could be more cost-effective in the clinical setting.
To develop the clinical applicability of the proposed strategy, we also show that DC transfected with RNA encoding a GITR-L fusion protein is comparable to anti-GITR-secreting DC in their ability to augment DC-based tumor vaccination ( Figure 5 ). The advantage of a fusion protein is that an antibody does not have to be generated and it is relatively simple to construct a cDNA that encodes an entirely syngeneic Ig fragment fused to the natural ligand. Recent studies have established the efficacy of systemic administration of GITR-L fusion protein to mice. 42, 43 As an anti-human GITR mAbproducing hybridoma is currently unavailable to us, we have constructed a plasmid to generate human GITR-L/ human Fc fusion protein RNA and are generating preclinical functional data using human immunoassays.
The agonistic anti-GITR, DTA-1, was chosen because it has been used in numerous studies to enhance T cellmediated immunity to tumors and infectious agents. [22] [23] [24] [25] [26] [27] [28] [29] [30] Although some studies indicate that GITR ligation in mice leads to abrogation of Treg-mediated suppression, 27, 44 others show that the function of GITR may be due to direct costimulation and expansion of T-cell subsets 23, 26, 33, [45] [46] [47] possibly rendering the effector T cells resistant to Treg suppression. 28, 32, 39, 48 Consistent with these published results, our data suggest that anti-GITRsecreting DC synergize with antigen-presenting DC to stimulate and expand T-cell subsets (Figure 4a ) and enhance effector T-cell function (Figure 4b) . Additionally, GITR-mediated stimulation of effector T cells using anti-GITR-secreting DC renders them resistant to Treg suppression in vitro (Supplementary Figure 1) . In preliminary experiments, Treg depletion (using clone PC61) before tumor implantation and vaccination with antigen-presenting DC and anti-GITR-secreting DC does not further augment anti-GITR-mediated anti-tumor immunity (data not shown). Notably, depletion of CD8 þ or CD4 þ T cells completely abrogates tumor immune responses in immunized mice, suggesting that the anti-GITR-stimulated effector T cells were responsible for enhanced tumor immunity (data not shown). Experiments dissecting the role of individual T-cell subsets in mice coimmunized with antigen-presenting and anti-GITR-secreting DC are ongoing.
The concept that we have shown is not limited to the immunostimulatory molecule targeted in this study. We have now extended this strategy to target the immune receptors CTLA-4 and CD25 in murine tumor models. Currently, we are testing DC transfected with the RNA encoding mAbs against OX40 and 4-1BB, separately, and in combinations with those against GITR and CTLA-4 for their ability to enhance anti-tumor immunity. Moreover, the strategy we have proposed can be used to transfect cells other than DC. For example, tumorspecific T cells transfected with antibody-encoding RNA can be used in adoptive immunotherapy strategies to ensure that the tumor-specific T cells are resistant to intratumoral Tregs and/or suppressive cytokines such as TGF-b. The proposed technique of modulating immune responses by using cells to deliver immunomodulating molecules to the site of function is a broadly applicable and clinically feasible approach that holds promise in the field of immunotherapy.
